Spin-out company gets approval for new nicotine gum

July 14, 2011 in Health
Spin-out company gets approval for new nicotine gum

A new generation of nicotine gum, developed by the University of Bristol spin-out company Revolymer® Ltd, has been given approval for sale in Canada. The gum uses new technology to mask the nicotine taste.

The approval, by the Natural Health Products Directorate of Canada, is the first step in Revolymer’s global strategy to release a nicotine gum that not only helps smokers quit but also offers a great chew. The gum will be distributed in Canada by sales and marketing partner, SDS Pharma.

The current market for nicotine now totals $1.6bn world-wide, yet there has been little innovation of the product over the last 20 years.  Many smokers who try to quit using gum are put off by the taste of the existing products. Revolymer has applied its proprietary technology which not only controls the release of nicotine but also helps to mask its bitter taste through molecular encapsulation.  The product has been scaled up by a manufacturing partner with 2.5 million pieces of gum made in both 2 and 4 mg doses with flavours of spearmint, peppermint and fresh fruit.

“Over the past year, we have been applying our environmentally friendly chewing gum technology to functional chewing gums and our first goal was to develop a nicotine gum with an improved taste to help people to quit smoking” said Roger Pettman, Chairman and Chief Executive Officer of Revolymer.

“Achieving regulatory approval so quickly is another key milestone for Revolymer and I am also delighted to be working closely with Greg and the team at SDS Pharma”.

Greg Kelly, President of SDS Pharma added, “We at SDS Pharma Partners are very excited to be working with Revolymer on the introduction of new nicotine replacement gums to Canada.

“Consumer and customer responses have demanded improved taste and a more pleasant mouth-feel versus the currently marketed products. Revolymer meets and exceeds those demands and the resulting user experience is superb.

“One of our key goals is bringing innovative new products to the Canadian marketplace, and delivering superior sales and profit to the retail trade. The Canadian market for chewing gum is the fourth biggest in the world and Canadians chew more than 120 million pieces a year, so we look forward to establishing Revolymer as a valued supplier in Canada and expanding their presence with innovative solutions.”

About Revolymer

Revolymer is a rapidly growing technology development company founded by Roger Pettman with Terence Cosgrove and Lieven De Smedt based on the technology developed by Professor Terence Cosgrove at the University of Bristol.

Using commercially available and inexpensive polymers, Revolymer applies its innovative proprietary approach to formulate novel polymers to revolutionise consumer products.  REV7, a removable, degradable chewing gum with excellent flavour and chew characteristics was its first commercial product.

Current applications for the Company’s technology are in the Confectionery Chewing Gum, Medicated Chewing Gum, Household Products, Personal Care and Coatings & Adhesives sectors of the FMCG (Fast Moving Consumer Goods) industry.

Provided by University of Bristol search and more info website

not rated yet  

Rank not rated yet
Related Stories
Relevant PhysicsForums posts

More news stories

Early physical therapist treatment associated with reduced risk of healthcare utilization and reduced overall healthcare

A new study published in Spine shows that early treatment by a physical therapist for low back pain (LBP), as compared to delayed treatment, was associated with reduced risk of subsequent healthcare utilization and lower ...

Health created 1 hour ago | popularity not rated yet | comments 0 | with audio podcast

Cancer patients share web info with docs for insight, advice

(HealthDay) -- Cancer patients' primary goal in talking with their doctors about information they've found on the Internet is to get more insight and advice on the online information, new research indicates.

Health created 4 hours ago | popularity not rated yet | comments 0

P&G to add latches to make detergent packs safer

(AP) -- Procter & Gamble says it will change the design of packaging for its miniature laundry detergent product to deter children from eating the brightly colored packets that look like candy.

Health created 4 hours ago | popularity not rated yet | comments 0

In Spain, 70 percent of women use contraceptives during their first sexual encounter

Contraceptive use in Spain during the first sexual encounter is similar to other European countries. However, there are some geographical differences between Spanish regions: women in Murcia use contraceptives ...

Health created 5 hours ago | popularity not rated yet | comments 0

WHO target to cut early chronic illness deaths

The World Health Organization announced on Friday it was set to approve a new target to reduce premature deaths from chronic illnesses such as heart disease by a quarter by 2025.

Health created 6 hours ago | popularity not rated yet | comments 0


Of mice and mental models: Neuroscientific implications of risk-optimized behavior in the mouse

(Medical Xpress) -- Regardless of an organism’s biological complexity, every encephalized animal continuously makes under-informed behavioral choices that can have serious consequences. Despite its ubiquity, ...

Cancer may require simpler genetic mutations than previously thought

Chromosomal deletions in DNA often involve just one of two gene copies inherited from either parent. But scientists haven't known how a deletion in one gene from one parent, called a "hemizygous" deletion, can contribute ...

Skp2 activates cancer-promoting, glucose-processing Akt

HER2 and its epidermal growth factor receptor cousins mobilize a specialized protein to activate a major player in cancer development and sugar metabolism, scientists report in the May 25 issue of Cell.

Inherited DNA change explains overactive leukemia gene

A small inherited change in DNA is largely responsible for overactivating a gene linked to poor treatment response in people with acute leukemia.

Implantable pain disk may help those with cancer

An estimated 3.5 million cancer patients around the globe are in severe pain from their disease, but many get no relief.

First study to suggest that the immune system may protect against Alzheimer's changes in humans

Recent work in mice suggested that the immune system is involved in removing beta-amyloid, the main Alzheimer's-causing substance in the brain. Researchers have now shown for the first time that this may apply in humans.